Health Care/Hospital
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...
2025-04-08 15:38
2719
2025 ZGC Forum: Gala for Global Sci-tech Cooperation
BEIJING, April 7, 2025 /PRNewswire/ -- A report from Science and Technology Daily: The 2025 Zhongguancun Forum Annual Conference (2025 ZGC Forum), with a focus on new quality productive forces, concluded onMarch 31, with significant results and promotion of international sci-tech cooperation. &a...
2025-04-07 21:45
2230
Duality Bio Appoints Hua Mu as Global Chief Medical Officer
SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company...
2025-04-07 12:52
2440
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy fo...
2025-04-07 08:00
2378
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...
2025-04-06 10:12
3337
I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S.
– Age-Reversed Stem Cell Technology Now Available to the Public –
PALO ALTO, Calif., April 5, 2025 /PRNewswire/ -- I Peace, Inc. (
https://ipeace.com/en/
2025-04-05 20:00
2944
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveTuesday, April 15, 2025, with trading to begin on a split-adjusted basi...
2025-04-05 04:05
6048
ITRI Wins Seven 2025 Edison Awards for Groundbreaking Technologies
FORT MYERS, Fla., April 4, 2025 /PRNewswire/ -- The Industrial Technology
Research Institute (ITRI
2025-04-05 02:05
4083
Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation
BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co.,
Ltd.
2025-04-04 20:58
4456
NUS researchers combine 3D bioprinting with AI to personalise oral soft tissue grafts
Artificial intelligence streamlines the optimisation of bioprinting parameters for oral soft tissue grafts, reducing time and resource demands while enabling efficient, personalised dental treatments SINGAPORE, April 4, 2025 /PRNewswire/ -- A team of researchers from the National University of S...
2025-04-04 11:43
3694
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund")...
2025-04-03 19:30
6297
Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth
BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary ofChina's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, sol...
2025-04-03 15:25
4079
HiTouch, a Mobile App that Improves the Happiness of Individuals and Organizations
SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- As the social atmosphere emphasizes the importance of mental health care and depression prevention, the number of companies providing related services is increasing. HiTouch, a recently launched mobile app for measuring happiness, is attracting at...
2025-04-03 07:00
2408
TCI Biotech Expands US Glass Bottling Capabilities for Liquid Nutraceuticals Innovation
TAIPEI, April 2, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling solution for liquid supplements, positioning it as a cornerstone of its expanded CDMO+ services. Designed...
2025-04-03 00:00
3312
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...
2025-04-02 22:00
3103
So-Young International Inc. Announces Share Purchase by Controlling Shareholder
BEIJING, April 2, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform inChina connecting consumers with online services and offline treatments, today announced that the Company had been informed by Mr.Xing Jin, the ...
2025-04-02 18:00
4618
Data4Life releases Data2Evidence as open source: a new chapter for global health research
POTSDAM, Germany, April 2, 2025 /PRNewswire/ -- Data4Life, the nonprofit digital health organization, today announced the open-source release of its research platformData2Evidence (D2E). With this move, Data4Life is equipping researchers and developers worldwide with powerful tools to integrate, ...
2025-04-02 16:00
2173
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. * Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). * Tolerability & Disease Control Rate: Sho...
2025-04-02 15:56
2605
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, Ap...
2025-04-02 12:17
2463
Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug A...
2025-04-01 22:00
2831
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 271 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
